Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003025 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00003025: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00003025 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003025, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells. Combining vaccine therapy with surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients with stage I or stage II pancreatic cancer that has been surgically removed.
Interventions
- BIOLOGICAL vitespen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 1997-03 |
| Est. Completion | 2002-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003025
The ClinicalTrials.gov registry entry for NCT00003025 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which vitespen is the first listed.
NCT00003025 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003025 about?
NCT00003025 is a clinical study titled "Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer". RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells. Combining vaccine therapy with surgery may be an effective treatment for pancreatic cancer. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating pati...
What is the current status of trial NCT00003025?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 1997-03. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00003025?
The interventions under investigation include: vitespen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003025?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.